依帕司他联合利拉鲁肽对2型糖尿病合并冠心病患者T细胞亚群及血清炎症因子水平的影响  

Effect of Epalrestat Combined with Liraglutide on T Cell Subsets and Serum Inflammatory Factors in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease

作　　者：郭三敏 赵爽 李萌 GUO Sanmin;ZHAO Shuang;LI Meng(Xuchang People's Hospital,Xuchang Henan 461000,China;Xinxiang People's Hospital,Xinxiang Henan 453700,China;Jinhua First People's Hospital,Jinhua Zhejiang 321000,China)

机构地区：[1]许昌市人民医院,河南许昌461000 [2]新乡市人民医院,河南新乡453700 [3]金华市第一人民医院,浙江金华321000

出　　处：《药品评价》2024年第3期308-311,共4页Drug Evaluation

摘　　要：目的 探讨依帕司他联合利拉鲁肽对2型糖尿病(T2DM)合并冠心病(CHD)患者的应用效果。方法 选取许昌市人民医院2020年3月至2023年6月收治的100例T2DM合并CHD患者为研究对象,按照双色球法将其随机分为对照组(红色球)、研究组(蓝色球),各50例。对照组采用利拉鲁肽治疗,研究组采用利拉鲁肽联合依帕司他治疗。比较两组临床疗效,心功能指标[左室射血分数(LVEF)、舒张早期最大峰值速度/舒张晚期最大峰值速度(E/A)],血糖指标 [空腹血糖(FPG)、餐后2 h血糖(2 hPG)],炎性因子[肿瘤坏死因子(TNF-α)、C反应蛋白(CRP)、白细胞介素(IL)-4、IL-6],T细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))和不良反应。结果 研究组疗效96.00 %高于对照组82.00 %(P<0.05)。治疗后,与对照组相比,研究组FPG、2 hPG水平更低,LVEF、E/A水平更高(P<0.05);研究组CD3^(+)、CD4^(+)/CD8^(+)及CD4^(+)水平高于对照组(P<0.05);研究组TNF-α、CRP、IL-6水平低于对照组,IL-4水平高于对照组(P<0.05)。治疗后两组CD8^(+)水平、不良反应发生率相比,差异无统计学意义(P>0.05)。结论 依帕司他联合利拉鲁肽对治疗T2DM合并CHD患者疗效确切,可抑制促炎因子表达,增强免疫功能及心功能,有效控糖,且安全性好。Objective To investigate the efficacy of epalrestat combined with liraglutide in patients with type 2 diabetes mellitus(T2DM)and coronary heart disease(CHD).Methods A total of 100 patients with T2DM complicated with CHD admitted to Xuchang People's Hospital from March 2020 to June 2023 were selected as the study objects,and were randomly divided into control group(red ball)and study group(blue ball)according to the two-color sphere method,with 50 cases each.The control group was treated with liraglutide,and the study group was treated with liraglutide combined with epalrestat.The clinical efficacy,cardiac function indicators(LVEF,E/A),blood glucose indicators(2 hPG,FPG),Inflammatory factors(TNF-α,CRP,IL-4,IL-6),T cell subsets(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+))and adverse reactions were compared between the two groups.Results The efficacy of the study group was 96.00%higher than that of the control group 82.00%(P<0.05).After treatment,compared with the control group,the levels of FPG and 2 hPG in the study group were lower,and the levels of LVEF and E/A were higher(P<0.05);the levels of CD3^(+),CD4^(+)/CD8^(+)and CD4^(+)in study group were higher than those in control group(P<0.05);the levels of TNF-α,CRP and IL-6 in the study group were lower than those in the control group,and the levels of IL-4 were higher than those in the control group(P<0.05).There were no significant differences in CD8^(+)level and incidence of adverse reactions between 2 groups after treatment(P>0.05).Conclusion Epalrestat combined with liraglutide is effective in the treatment of T2DM patients with CHD.It can inhibit the expression of pro-inflammatory factors,enhance immune function and cardiac function,effectively control sugar,and is safe.

关 键 词：依帕司他 利拉鲁肽 2型糖尿病 冠心病 T细胞亚群 

分 类 号：R587.1[医药卫生—内分泌] R541.4[医药卫生—内科学]